{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T03:00:12Z","timestamp":1760151612355,"version":"build-2065373602"},"reference-count":80,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Treatment of metastatic prostate cancer was historically performed via bilateral orchiectomy to achieve castration. An alternative to surgical castration is the administration of subcutaneous recombinant luteinizing hormone-releasing hormone (LHRH). LHRH causes the pituitary gland to produce luteinizing hormone (LH), which results in synthesis and secretion of testosterone from the testicles. When LHRH levels are continuously high, the pituitary gland stops producing LH, which results in reduced testosterone production by the testicles. Long-acting formulations of LHRH were developed, and its use replaced surgical orchiectomy in the vast majority of patients. Combining LHRH and radiation therapy was shown to increase survival of prostate cancer patients with locally advanced disease. Here, we present a hypothesis, and preliminary evidence based on previous randomized controlled trials, that androgen surge during radiation, rather than its suppression, could be responsible for the enhanced prostate cancer cell kill during radiation. Starting LHRH agonist on the first day of radiation therapy, as in the EORTC 22863 study, should be the standard of care when treating locally advanced prostate cancer. We are developing formulations of short-acting LHRH agonists that induce androgen flare, without subsequent androgen deprivation, which could open the door for an era in which locally advanced prostate cancer could be cured while patients maintain potency.<\/jats:p>","DOI":"10.3390\/cancers14081959","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T21:33:42Z","timestamp":1649885622000},"page":"1959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Nicola J.","family":"Nasser","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Albany Medical College, Albany, NY 12208, USA"},{"name":"The Umbilicus Inc., Nonprofit Organization for Preserving Sexual Function of Individuals with Cancer Below the Umbilicus, New York, NY 10032, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,13]]},"reference":[{"key":"ref_1","first-page":"293","article-title":"Studies on prostatic cancer","volume":"1","author":"Huggins","year":"1941","journal-title":"Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1139\/y55-054","article-title":"The release of corticotrophin by anterior pituitary tissue in vitro","volume":"33","author":"Saffran","year":"1955","journal-title":"Can. J. Biochem. Physiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S0006-291X(71)80019-0","article-title":"Structure of the porcine LH-and FSH-releasing hormone. I. The proposed amino acid sequence","volume":"43","author":"Matsuo","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/0006-291X(71)90623-1","article-title":"Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analyses","volume":"44","author":"Baba","year":"1971","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tree, A., Griffin, C., Syndikus, I., Birtle, A., Choudhury, A., Graham, J., Ferguson, C., Khoo, V., Malik, Z., and O\u2019Sullivan, J. (2022). Non-randomised comparison of efficacy and side effects of bicalutamide compared with LHRH analogues in combination with radiotherapy in the xxxxxx trial. Int. J. Radiat. Oncol. Biol. Phys., in press.","DOI":"10.1016\/j.ijrobp.2021.12.160"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Leuprolide Study Group (1984). Leuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer. N. Engl. J. Med., 311, 1281\u20131286.","DOI":"10.1056\/NEJM198411153112004"},{"key":"ref_9","first-page":"68","article-title":"Switching Patients with Prostate Cancer from GnRH Antagonist to Long-acting LHRH Agonist for Androgen Deprivation: Reducing Hospital Visits during the Coronavirus Pandemic","volume":"22","author":"Fujiwara","year":"2021","journal-title":"Bone"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.clinthera.2009.11.009","article-title":"Degarelix: A gonadotropin-releasing hormone antagonist for the management of prostate cancer","volume":"31","author":"Steinberg","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant\/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12610-018-0074-2","article-title":"A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer","volume":"28","author":"Asakawa","year":"2018","journal-title":"Basic Clin. Androl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/j.1442-2042.2012.02997.x","article-title":"Gonadotropin-releasing hormone: An update review of the antagonists versus agonists","volume":"19","author":"Klotz","year":"2012","journal-title":"Int. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"695170","DOI":"10.3389\/fendo.2021.695170","article-title":"Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences from Randomized and Real-World Studies","volume":"12","author":"Sciarra","year":"2021","journal-title":"Front. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","article-title":"The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group","volume":"102","author":"Klotz","year":"2008","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/BF02564863","article-title":"Influence of luteinizing hormone-releasing hormone analogues on serum levels of prostatic acid phosphatase and prostatic specific antigen in patients with metastatic carcinoma of the prostate","volume":"30","author":"Sasagawa","year":"1998","journal-title":"Int. Urol. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1464-410x.2001.00988.x","article-title":"Nonsteroidal antiandrogens: A therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function","volume":"87","author":"Iversen","year":"2001","journal-title":"BJU Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh","year":"2010","journal-title":"Urology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.urolonc.2014.04.016","article-title":"Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact","volume":"33","author":"Vis","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.euf.2017.06.008","article-title":"Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth","volume":"5","author":"Krakowsky","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): A randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103681","DOI":"10.1016\/j.ebiom.2021.103681","article-title":"Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer","volume":"73","author":"Mout","year":"2021","journal-title":"eBioMedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15085","DOI":"10.1073\/pnas.0603057103","article-title":"Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells","volume":"103","author":"Litvinov","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1056\/NEJM194212032272302","article-title":"The Treatment of Cancer of the Prostate with Castration and the Administration of Estrogen: A Preliminary Report","volume":"227","author":"Chute","year":"1942","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus Continuous Androgen Deprivation in Prostate Cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/pcan.2016.25","article-title":"A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients","volume":"19","author":"Kiwata","year":"2016","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nasser, N.J., Sun, K., Scanlon, K.M., Mishra, M.V., and Molitoris, J.K. (2022). Administering Docetaxel for Metastatic Hormone Sensitive Prostate Cancer 1\u20136 Days Compared to More than 14 Days After the Start of LHRH Agonist is Associated with Better Clinical Outcomes Due to Androgen Flare. Cancers, 14.","DOI":"10.3390\/cancers14040864"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/cc.6.7.4050","article-title":"Telling cells how to die: Docetaxel therapy in cancer cell lines","volume":"6","author":"Palacios","year":"2007","journal-title":"Cell Cycle"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0093-7754(01)90148-4","article-title":"Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer","volume":"28","author":"Pienta","year":"2001","journal-title":"Semin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"111824","DOI":"10.1016\/j.biopha.2021.111824","article-title":"New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities","volume":"141","author":"Ashrafizadeh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/jcp.21522","article-title":"Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells","volume":"217","author":"Fabbri","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.2021.39.6_suppl.116","article-title":"Preliminary results from a phase II trial of docetaxel before castration with degarelix in men with newly diagnosed metastatic prostate cancer","volume":"39","author":"Gourdin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/sj.bjc.6603129","article-title":"Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles","volume":"94","author":"Kramer","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_40","first-page":"5031","article-title":"Combined treatment with stattic and docetaxel alters the Bax\/Bcl-2 gene expression ratio in human prostate cancer cells","volume":"17","author":"Mohammadian","year":"2016","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_45","unstructured":"Hall, E.J., and Giaccia, A.J. (2019). Radiobiology for the Radiologist, Wolters Kluwer. [8th ed.]."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: Updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13014-018-1040-z","article-title":"The alfa and beta of tumours: A review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies","volume":"13","author":"Oei","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13014-014-0275-6","article-title":"Hypofractionated radiotherapy for prostate cancer","volume":"9","author":"Hegemann","year":"2014","journal-title":"Radiat. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0360-3016(00)01383-3","article-title":"Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy","volume":"49","author":"Wilder","year":"2001","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2019.07.008","article-title":"Estimation of the \u03b1\/\u03b2 ratio of non-small cell lung cancer treated with stereotactic body radiotherapy","volume":"142","author":"Klement","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0360-3016(02)03828-2","article-title":"How low is the alpha\/beta ratio for prostate cancer","volume":"55","author":"Wang","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the Alpha\/Beta Ratio for Prostate Cancer in the Presence of an Overall Time Factor: Bad News, Good News, or No News","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ijrobp.2010.12.040","article-title":"Later Outcomes and Alpha\/Beta Estimate from Hypofractionated Conformal Three-Dimensional Radiotherapy Versus Standard Fractionation for Localized Prostate Cancer","volume":"82","author":"Leborgne","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.brachy.2010.02.196","article-title":"Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT","volume":"9","author":"Deutsch","year":"2010","journal-title":"Brachytherapy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013Long-term results of phase III RTOG 85-31","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): Long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of Androgen Suppression in the Treatment of Prostate Cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1200\/JCO.2003.11.023","article-title":"Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92\u201302","volume":"21","author":"Hanks","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.ijrobp.2007.04.003","article-title":"An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone\/radiation interactions","volume":"69","author":"Lawton","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: An individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2008.09.024","article-title":"Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth","volume":"55","author":"Morgentaler","year":"2009","journal-title":"Eur. Urol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00019442-199902000-00004","article-title":"Testosterone and Depression in Aging Men","volume":"7","author":"Seidman","year":"1999","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/ncpendmet1050","article-title":"Testosterone and ill-health in aging men","volume":"5","author":"Yeap","year":"2009","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.juro.2014.07.123","article-title":"The Relationship between Total Testosterone Levels and Prostate Cancer: A Review of the Continuing Controversy","volume":"193","author":"Klap","year":"2015","journal-title":"J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"269ra2","DOI":"10.1126\/scitranslmed.3010563","article-title":"Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study","volume":"7","author":"Schweizer","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mohammad, O.S., Nyquist, M.D., Schweizer, M.T., Balk, S.P., Corey, E., Plymate, S., Nelson, P.S., and Mostaghel, E.A. (2017). Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions. Cancers, 9.","DOI":"10.3390\/cancers9120166"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.1158\/0008-5472.CAN-20-3607","article-title":"Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer","volume":"81","author":"Kumar","year":"2021","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Nordeen, S.K., Su, L.-J., Osborne, G.A., Hayman, P.M., Orlicky, D.J., Wessells, V.M., van Bokhoven, A., and Flaig, T.W. (2021). Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. Life, 11.","DOI":"10.3390\/life11090884"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S311","DOI":"10.21037\/atm.2019.10.32","article-title":"Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC)","volume":"7","author":"Isaacs","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eururo.2019.05.042","article-title":"Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts","volume":"77","author":"Lam","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Denmeade, S., Antonarakis, E.S., and Markowski, M.C. (2022). Bipolar androgen therapy (BAT): A patient\u2019s guide. Prostate, 1\u201310.","DOI":"10.1002\/pros.24328"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e05433","DOI":"10.1002\/ccr3.5433","article-title":"Clinical response in metastatic castration-resistant prostate cancer (mCRPC) cases treated with supra-physiological doses of testosterone: Bipolar androgen therapy","volume":"10","author":"Hoshi","year":"2022","journal-title":"Clin. Case Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejca.2020.11.043","article-title":"Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy","volume":"144","author":"Sena","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41388-021-02060-5","article-title":"The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells","volume":"41","author":"Mirzakhani","year":"2022","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijrobp.2006.07.045","article-title":"21: Androgen Deprivation Reduces Hypoxia in Human Prostate Cancer","volume":"66","author":"Milosevic","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-0842-03","article-title":"Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel","volume":"10","author":"Baker","year":"2004","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:53:12Z","timestamp":1760136792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/8\/1959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":80,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["cancers14081959"],"URL":"https:\/\/doi.org\/10.3390\/cancers14081959","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}